Calithera Biosciences Inc.
| NASDAQ: CALA | Healthcare / Biotechnology / USA |
| 2.05 | -0.1100 | -5.09% | Vol 824.81K | 1Y Perf -67.07% |
| Apr 20th, 2021 16:00 DELAYED |
| BID | 2.05 | ASK | 2.06 | ||
| Open | 2.14 | Previous Close | 2.16 | ||
| Pre-Market | - | After-Market | 2.07 | ||
| - - | 0.02 0.98% |
| Target Price | 3.33 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 62.44 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Market Cap | 150.30M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 0.37 | Earnings Date | 6th May 2021 |
Today's Price Range 2.032.15 | 52W Range 2.037.42 | 5 Year PE Ratio Range -4.20-4.20 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.39% | ||
| 1 Month | -25.18% | ||
| 3 Months | -30.03% | ||
| 6 Months | -42.58% | ||
| 1 Year | -67.07% | ||
| 3 Years | -66.39% | ||
| 5 Years | -65.25% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -53.78 | |||
ROE last 12 Months | -70.03 | |||
ROA (5Y Avg) | -41.18 | |||
ROA last 12 Months | -58.28 | |||
ROC (5Y Avg) | -54.20 | |||
ROC last 12 Months | -70.41 | |||
Return on invested Capital Q | -18.98 | |||
Return on invested Capital Y | -70.38 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.60 | ||||
| 1.54 | ||||
| - | ||||
| 14.70 | ||||
| -2.70 | ||||
| -1.23 | ||||
| 1.54 | ||||
| 1.40 | ||||
| 49.20M | ||||
| Forward PE | -3.02 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.30 | ||||
| 6.50 | ||||
| 0.04 | ||||
| 0.07 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.32 | -0.32 | 0.00 |
| Q03 2020 | -0.31 | -0.32 | -3.23 |
| Q02 2020 | -0.33 | -0.29 | 12.12 |
| Q01 2020 | -0.37 | -0.38 | -2.70 |
| Q04 2019 | -0.39 | -0.39 | 0.00 |
| Q03 2019 | -0.49 | -0.38 | 22.45 |
| Q02 2019 | -0.55 | -0.58 | -5.45 |
| Q01 2019 | -0.43 | -0.61 | -41.86 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.27 | 3.57 | Positive |
| 6/2021 QR | -0.23 | 4.17 | Positive |
| 12/2021 FY | -0.85 | 2.30 | Positive |
| 12/2022 FY | -0.71 | 12.35 | Positive |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.27 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 824.81K |
| Shares Outstanding | 73.32M |
| Trades Count | 3.80K |
| Dollar Volume | 3.07M |
| Avg. Volume | 1.57M |
| Avg. Weekly Volume | 578.32K |
| Avg. Monthly Volume | 814.46K |
| Avg. Quarterly Volume | 1.11M |
Calithera Biosciences Inc. (NASDAQ: CALA) stock closed at 2.05 per share at the end of the most recent trading day (a -5.09% change compared to the prior day closing price) with a volume of 825.95K shares and market capitalization of 150.30M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Calithera Biosciences Inc. CEO is Susan M. Molineaux.
The one-year performance of Calithera Biosciences Inc. stock is -67.07%, while year-to-date (YTD) performance is -58.25%. CALA stock has a five-year performance of -65.25%. Its 52-week range is between 2.03 and 7.42, which gives CALA stock a 52-week price range ratio of 0.37%
Calithera Biosciences Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 1.54, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 14.70, a PEG ratio of 2.32, a ROA of -58.28%, a ROC of -70.41% and a ROE of -70.03%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Calithera Biosciences Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Calithera Biosciences Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Calithera Biosciences Inc. is Strong Buy (1), with a target price of $3.33, which is +62.44% compared to the current price. The earnings rating for Calithera Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Calithera Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Calithera Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.47, ATR14 : 0.18, CCI20 : -130.73, Chaikin Money Flow : -0.19, MACD : -0.27, Money Flow Index : 27.95, ROC : -10.74, RSI : 32.62, STOCH (14,3) : 17.02, STOCH RSI : 0.17, UO : 42.60, Williams %R : -82.98), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Calithera Biosciences Inc. in the last 12-months were: Keith Orford (Sold 2 447 shares of value $14 682 )
Calithera Biosciences Inc.
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
CEO: Susan M. Molineaux
Telephone: +1 650 870-1000
Address: 343 Oyster Point Boulevard, South San Francisco 94080, CA, US
Number of employees: 93
